Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally

Targeting early infection to prevent HIV-1 mucosal transmission

(2010) Ashley T. Haase   NATURE

Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation

(2010) Martin P. Cranage et al.   VACCINE

Determinants and Correlation of Systemic and Cervical Concentrations of Total IgA and IgG

(2009) M. Safaeian et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Polyclonal expansion of cervical cytobrush-derived T cells to investigate HIV-specific responses in the female genital tract

(2009) Alfred Bere et al.   IMMUNOLOGY

Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection

(2009) Jiri Mestecky et al.   JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses

(2009) M P Cranage et al.   Mucosal Immunology

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis

(2009) D Tudor et al.   Mucosal Immunology

Visualizing Antigen-Specific and Infected Cells in Situ Predicts Outcomes in Early Viral Infection

(2009) Q. Li et al.   SCIENCE

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses

(2009) Rhonda M. Curran et al.   VACCINE

Impact of Mucosal Inflammation on Cervical Human Immunodeficiency Virus (HIV-1)-Specific CD8 T-Cell Responses in the Female Genital Tract during Chronic HIV Infection

(2008) P. P. Gumbi et al.   JOURNAL OF VIROLOGY

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study

(2007) Gilles Pialoux et al.   VACCINE